Gender and Ethnic Inequities in Gout Burden and Management.

[1]  K. Petrie,et al.  Internalized and Anticipated Stigmatization in Patients With Gout , 2019, ACR open rheumatology.

[2]  J. Singh,et al.  Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort , 2019, The Journal of Rheumatology.

[3]  P. Reid,et al.  Why cultural safety rather than cultural competency is required to achieve health equity: a literature review and recommended definition , 2019, International Journal for Equity in Health.

[4]  B. Arroll,et al.  Making the right thing the easy thing to do: strategies to improve outcomes in gout. , 2019, The Lancet. Rheumatology.

[5]  C. Frampton,et al.  The challenges of managing gout in primary care: Results of a best-practice audit. , 2019, Australian journal of general practice.

[6]  P. Gow,et al.  Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach. , 2019, Journal of primary health care.

[7]  Hyon K. Choi,et al.  Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016 , 2019, Arthritis & rheumatology.

[8]  N. Rashid,et al.  Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. , 2019, The American journal of medicine.

[9]  M. Marmot,et al.  Social determinants and non-communicable diseases: time for integrated action , 2019, BMJ.

[10]  N. Dalbeth,et al.  Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. , 2018, The New Zealand medical journal.

[11]  H. Kirchner,et al.  Improved Gout Outcomes in Primary Care Using a Novel Disease Management Program: A Pilot Study , 2018, Arthritis care & research.

[12]  T. Conner,et al.  Improving gout education from patients' perspectives: a focus group study of Māori and Pākehā people with gout. , 2018, Journal of primary health care.

[13]  L. Duley,et al.  Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial , 2018, The Lancet.

[14]  G. Treharne,et al.  Education Preferences of People With Gout: Exploring Differences Between Indigenous and Nonindigenous Peoples from Rural and Urban Locations , 2018, Arthritis care & research.

[15]  K. Saag,et al.  Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study , 2017, Rheumatology.

[16]  R. Terkeltaub,et al.  Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial , 2017, Arthritis & rheumatology.

[17]  J. Hindmarsh,et al.  Population‐Specific Resequencing Associates the ATP‐Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men , 2017, Arthritis & rheumatology.

[18]  J. Callear,et al.  Gout in primary care: Can we improve patient outcomes? , 2017, BMJ quality improvement reports.

[19]  Katherine K. Kim,et al.  Pilot study of a multidisciplinary gout patient education and monitoring program. , 2017, Seminars in arthritis and rheumatism.

[20]  R. Terkeltaub,et al.  Sex differences in gout characteristics: tailoring care for women and men , 2017, BMC Musculoskeletal Disorders.

[21]  Hyon K. Choi,et al.  The unclosing premature mortality gap in gout: a general population-based study , 2017, Annals of the rheumatic diseases.

[22]  K. Saag,et al.  Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study) , 2017, Arthritis & rheumatology.

[23]  A. So,et al.  Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) , 2016, Annals of the rheumatic diseases.

[24]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[25]  J. Singh,et al.  Racial differences in health-related quality of life and functional ability in patients with gout , 2017, Rheumatology.

[26]  K. Petrie,et al.  “You Don't Have to Be a Drinker to Get Gout, But It Helps”: A Content Analysis of the Depiction of Gout in Popular Newspapers , 2016, Arthritis care & research.

[27]  B. Arroll,et al.  A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management. , 2016, Journal of primary health care.

[28]  N. Dalbeth,et al.  Gout in Aotearoa New Zealand: are we going to ignore this for another 3 years? , 2016, The New Zealand medical journal.

[29]  A. V. Rij,et al.  Twenty-eight loci that influence serum urate levels: analysis of association with gout , 2014, Annals of the rheumatic diseases.

[30]  A. Avins,et al.  A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial. , 2016, The Permanente journal.

[31]  S. Ziebland,et al.  “Why me? I don’t fit the mould … I am a freak of nature”: a qualitative study of women’s experience of gout , 2015, BMC Women's Health.

[32]  N. McGill,et al.  Comprehensive dietary education in treated gout patients does not further improve serum urate , 2015, Internal medicine journal.

[33]  L. See,et al.  Epidemiology and management of gout in Taiwan: a nationwide population study , 2015, Arthritis Research & Therapy.

[34]  P. Clerson,et al.  Revisiting comorbidities in gout: a cluster analysis , 2013, Annals of the Rheumatic Diseases.

[35]  N. Dalbeth,et al.  Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers. , 2014, The New Zealand medical journal.

[36]  J. Singh.  The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout , 2014, Arthritis Research & Therapy.

[37]  J. Singh.  Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study , 2014, Arthritis Research & Therapy.

[38]  A. Avins,et al.  Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study , 2014, BMJ Open.

[39]  C. Elley,et al.  Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study. , 2013, Journal of primary health care.

[40]  K. Petrie,et al.  The experience and impact of gout in Māori and Pacific people: a prospective observational study , 2013, Clinical Rheumatology.

[41]  M. Doherty,et al.  Patient and provider barriers to effective management of gout in general practice: a qualitative study , 2012, Annals of the rheumatic diseases.

[42]  A. Wells,et al.  African American patients with gout: efficacy and safety of febuxostat vs allopurinol , 2012, BMC Musculoskeletal Disorders.

[43]  P. Macdonald,et al.  Women with gout: Efficacy and safety of urate‐lowering with febuxostat and allopurinol , 2012, Arthritis care & research.

[44]  P. Lipsky,et al.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.

[45]  N. Dalbeth,et al.  The Experience and Impact of Living With Gout: A Study of Men With Chronic Gout Using a Qualitative Grounded Theory Approach , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[46]  H. Schumacher,et al.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.

[47]  R. Terkeltaub,et al.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.

[48]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.

[49]  C. Kwoh,et al.  Gout in ambulatory care settings in the United States. , 2008, The Journal of rheumatology.

[50]  V. Strand,et al.  Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans , 2007, Annals of the rheumatic diseases.

[51]  J. Avorn,et al.  Uric acid lowering therapy: prescribing patterns in a large cohort of older adults , 2007, Annals of the rheumatic diseases.

[52]  N. Kleinman,et al.  The impact of gout on work absence and productivity. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[53]  R. Platt,et al.  Sex differences in gout epidemiology: evaluation and treatment , 2006, Annals of the rheumatic diseases.

[54]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[55]  H. Simmonds,et al.  Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. , 1994, British journal of rheumatology.

[56]  K. Bremner,et al.  Hyperuricaemia, gout and kidney function in New Zealand Maori men. , 1984, British journal of rheumatology.

[57]  A. Gutman,et al.  EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. , 1964, The American journal of medicine.

[58]  D. Mccarty,et al.  ACUTE ARTHRITIS IN MAN AND DOG AFTER INTRASYNOVIAL INJECTION OF SODIUM URATE CRYSTALS , 1962 .